Legend biotech announces 10 presentations at the 67th american society of hematology (ash) annual meeting

Two oral and seven poster presentations further support the carvykti® research in multiple myeloma first-in-human phase 1 data for allogeneic car-t cell therapy for nhl to be featured in oral session somerset, n.j., nov. 03, 2025 (globe newswire) -- legend biotech corporation (nasdaq: legn) (legend biotech), a global leader in cell therapy, today announced that it will present two oral presentations and seven poster presentations on carvykti® (ciltacabtagene autoleucel; cilta-cel) for multiple myeloma at the 67th annual american society of hematology (ash) annual meeting taking place from december 6-9, 2025, in orlando, fl.
ASH Ratings Summary
ASH Quant Ranking